Skip to main content

Research Repository

Advanced Search

All Outputs (4)

Physiologically relevant screening of polyphenol-rich commercial preparations for bioactivity in vascular endothelial cells and application to healthy volunteers: a viable workflow and a cautionary tale (2019)
Journal Article
Jones, H., Papageorgiou, M., Gordon, A., Ehtesham, Javed, Z., Wells, L. K., Greetham, S., Doyle, B., Hayes, N., Rigby, A., Atkin, S. L., Courts, F. L., & Sathyapalan, T. (2020). Physiologically relevant screening of polyphenol-rich commercial preparations for bioactivity in vascular endothelial cells and application to healthy volunteers: a viable workflow and a cautionary tale. Biochemical Pharmacology, 173, Article 113754. https://doi.org/10.1016/j.bcp.2019.113754

© 2019 Elsevier Inc. This study describes the screening of 13 commercially-available plant extracts for pharmacological activity modulating vascular function using an endothelial cell model. A French maritime pine bark extract (FMPBE) was found to ha... Read More about Physiologically relevant screening of polyphenol-rich commercial preparations for bioactivity in vascular endothelial cells and application to healthy volunteers: a viable workflow and a cautionary tale.

Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study (2019)
Journal Article
Javed, Z., Papageorgiou, M., Deshmukh, H., Rigby, A. S., Qamar, U., Abbas, J., Khan, A. Y., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2019). Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study. Clinical Endocrinology, 90(6), 805-813. https://doi.org/10.1111/cen.13968

Background: Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type 2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascu... Read More about Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study.

A randomized, controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome (2019)
Journal Article
Javed, Z., Papageorgiou, M., Deshmukh, H., Kilpatrick, E., Mann, V., Corless, L., Abouda, G., Rigby, A. S., Atkin, S., & Sathyapalan, T. (2019). A randomized, controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome. Nutrients, 11(1), 188. https://doi.org/10.3390/nu11010188

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. Polycystic ovary syndrome (PCOS) increases the risk of metabolic syndrome and non-alcoholic-fatty-liver disease (NAFLD). Vitamin D supplementation may exert positive effects on liver biochemis... Read More about A randomized, controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome.

Symptoms and exacerbations in asthma: an apparent paradox? (2019)
Journal Article
Morjaria, J. B., Rigby, A. S., & Morice, A. H. (2019). Symptoms and exacerbations in asthma: an apparent paradox?. Therapeutic Advances in Chronic Disease, 10, https://doi.org/10.1177/2040622319884387

© The Author(s), 2019. Background: There is a dearth of data on prospectively recorded symptoms in patients with uncontrolled asthma. Asthma symptoms and exacerbation rate are commonly thought to be associated. The aim of this study was to analyse as... Read More about Symptoms and exacerbations in asthma: an apparent paradox?.